Skip to main content
. 2023 May 24;15(11):2452. doi: 10.3390/nu15112452

Table 1.

Selected mechanisms of action of exercise on hepatic steatosis.

Mechanism of Action Effects on Hepatic Steatosis Animal Evidence Human Evidence Extrahepatic Benefits Safety
AMPK ↓ steatosis Aerobic and resistance training increases AMPK activation N.A. ↑ GLUT-4 expression Exercise is safe for people with NAFLD/NASH when supervised by an appropriately qualified exercise professional and with adequate screening and monitoring protocols.
↑ glucose uptake
FGF-19 and -21 ↓ steatosis Aerobic exercise training increases FGF receptor 1 and FGF receptor 2
Chronic exercise training increases β-klotho
Chronic exercise training reduces serum FGF-21
Aerobic and resistance training reduces serum FGF-21 ↑ hepatic glycogen synthesis
Effect of exercise on FGF-19 is unclear ↑ hepatic gluconeogenesis
GLP-1 ↓ steatosis N.A. Acute aerobic exercise ↑ GLP-1 ↑ weight loss
Short term high-intensity aerobic exercise reversed GLP-1 resistance ↑ insulin production
N.A. for chronic training adaptation ↓ appetite
Mitochondrial function and β-oxidation ↓ steatosis Exercise training improves mitochondrial function, ↑ mitochondrial content and ↑ β-oxidation Exercise training improves mitochondrial function, ↑ mitochondrial content and ↑ β-oxidation ↑ insulin sensitivity
UCP ↓ steatosis Aerobic exercise upregulates UCP-1 and reverses UCP-2 dysfunction in the liver N.A. Prevent oxidative stress
PPAR-α/γ ↓ steatosis Exercise training (moderate-intensity running or swimming; high-intensity interval training; resistance training) activates PPAR-α N.A. ↑ insulin sensitivity
Maternal aerobic exercise may protect against early life NAFLD in offspring
THR-β ↓ steatosis Aerobic exercise training increases T3 response index N.A. Acute exercise ↑ free T3 and T4
↑ mitochondria size and number
↑ glucose uptake
↑ gluconeogenesis
Chronic exercise ↑ T3 and T4 turnover at same absolute intensity

AMPK = adenosine monophosphate-activated protein kinase; FGF = fibroblast growth factor; GLP = glucagon-like peptide; GLUT = glucose transporter type; N.A. = not available; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; PPAR = peroxisome proliferator-activated receptor; T3 = triiodothyronine; T4 = thyroxine; THR = thyroid hormone receptor; UCP = mitochondrial uncoupling proteins.